TTrialPathMatch Me to Trials
← Back to trials
RecruitingSturge - Weber Syndrome (SWS)

Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome

Eligible age

0.1–1.5 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Patients with Sturge-Weber syndrome (SWS) are frequently affected by seizures, and seizures are associated with poorer neurological outcomes. To date there is no established means of predicting or preventing seizure onset. Cannabidiol (Epidiolex) was well tolerated in an open label study in this population. This trial will evaluate whether Epidiolex in presymptomatic Sturge-Weber patients may delay the onset of seizures and improve neurological outcome.

Sponsor: Johns Hopkins University

You may qualify if…

  • ✓ Clinical diagnosis of Sturge-Weber Syndrome.
  • ✓ Age 1 to 18 months of age, inclusive.
  • ✓ Neuroimaging demonstrating involvement of 3 or more lobes, or bilateral involvement.
  • ✓ No history of seizures.
  • ✓ Patient's parent or legal guardian provides written informed consent prior to treatment initiation.

You may not qualify if…

  • ✕ Any severe and/or uncontrolled medical conditions at randomization including, but not limited to the following:
  • ✕ Liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBVDNA and/or positive HbsAg, quantifiable HCV-RNA). Specifically the patient should not have either AST or ALT more than 1.5 times the upper limit of normal. The Child- Pugh Score must be A (mild) which is a score of 5-6 (minimum/normal score=5). Child-Turcotte-Pugh (CTP) Calculator - Clinical Calculators - Hepatitis C Online (uw.edu)
  • ✕ Uncontrolled diabetes as defined by fasting serum glucose \> 1.5 ULN
  • ✕ Active (acute or chronic) or uncontrolled severe infections
  • ✕ Active, bleeding diathesis
  • ✕ Any other neurological diagnosis that increases the risk of seizure or neurodevelopmental disability.
  • ✕ Patients who have had a major surgery or significant traumatic injury within 4 weeks of study entry, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study.
  • ✕ Prior treatment with any investigational drug or use of any other cannabis product within the preceding 4 weeks prior to study entry.

Where it's recruiting

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT07778810 · last updated 2026-10-02

Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome · TrialPath